Ipsen S.A. I7G.F Stock
Ipsen S.A. Price Chart
Ipsen S.A. I7G.F Financial and Trading Overview
| Ipsen S.A. stock price | 109.6 EUR |
| Previous Close | 117.1 EUR |
| Open | 115.3 EUR |
| Bid | 116.4 EUR x 30000 |
| Ask | 117.2 EUR x 30000 |
| Day's Range | 115.3 - 115.3 EUR |
| 52 Week Range | 91.7 - 122.2 EUR |
| Volume | 150 EUR |
| Avg. Volume | 14 EUR |
| Market Cap | 9.55B EUR |
| Beta (5Y Monthly) | 0.71196 |
| PE Ratio (TTM) | 23.578733 |
| EPS (TTM) | 7.4 EUR |
| Forward Dividend & Yield | 1.2 (1.01%) |
| Ex-Dividend Date | June 2, 2023 |
| 1y Target Est | N/A |
I7G.F Valuation Measures
| Enterprise Value | 9.95B EUR |
| Trailing P/E | 23.578733 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.9104748 |
| Price/Book (mrq) | 2.8013315 |
| Enterprise Value/Revenue | 3.033 |
| Enterprise Value/EBITDA | 9.352 |
Trading Information
Ipsen S.A. Stock Price History
| Beta (5Y Monthly) | 0.71196 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 122.2 EUR |
| 52 Week Low | 91.7 EUR |
| 50-Day Moving Average | 112.21 EUR |
| 200-Day Moving Average | 107 EUR |
I7G.F Share Statistics
| Avg. Volume (3 month) | 14 EUR |
| Avg. Daily Volume (10-Days) | 45 EUR |
| Shares Outstanding | 82.84M |
| Float | 30.59M |
| Short Ratio | N/A |
| % Held by Insiders | 57.07% |
| % Held by Institutions | 19.69% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 1.2 |
| Trailing Annual Dividend Yield | 1.02% |
| 5 Year Average Dividend Yield | 115.99% |
| Payout Ratio | 0.24540001 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | June 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 13.69% |
| Operating Margin (ttm) | 26.53% |
| Gross Margin | 83.07% |
| EBITDA Margin | 32.42% |
Management Effectiveness
| Return on Assets (ttm) | 9.38% |
| Return on Equity (ttm) | 12.52% |
Income Statement
| Revenue (ttm) | 3.28B EUR |
| Revenue Per Share (ttm) | 39.77 EUR |
| Quarterly Revenue Growth (yoy) | 8.40% |
| Gross Profit (ttm) | 2.63B EUR |
| EBITDA | 1.06B EUR |
| Net Income Avi to Common (ttm) | 406.2M EUR |
| Diluted EPS (ttm) | 4.89 |
| Quarterly Earnings Growth (yoy) | -50.50% |
Balance Sheet
| Total Cash (mrq) | 413.4M EUR |
| Total Cash Per Share (mrq) | 5 EUR |
| Total Debt (mrq) | 681.7M EUR |
| Total Debt/Equity (mrq) | 20.03 EUR |
| Current Ratio (mrq) | 1.029 |
| Book Value Per Share (mrq) | 41.159 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 971.5M EUR |
| Levered Free Cash Flow (ttm) | 1.16B EUR |
Profile of Ipsen S.A.
| Country | Germany |
| State | N/A |
| City | Boulogne-Billancourt |
| Address | 65, quai Georges Gorse |
| ZIP | 92100 |
| Phone | 33 1 58 33 50 00 |
| Website | https://www.ipsen.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 5300 |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Q&A For Ipsen S.A. Stock
What is a current I7G.F stock price?
Ipsen S.A. I7G.F stock price today per share is 109.6 EUR.
How to purchase Ipsen S.A. stock?
You can buy I7G.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ipsen S.A.?
The stock symbol or ticker of Ipsen S.A. is I7G.F.
Which industry does the Ipsen S.A. company belong to?
The Ipsen S.A. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Ipsen S.A. have in circulation?
The max supply of Ipsen S.A. shares is 82.7M.
What is Ipsen S.A. Price to Earnings Ratio (PE Ratio)?
Ipsen S.A. PE Ratio is 14.81081000 now.
What was Ipsen S.A. earnings per share over the trailing 12 months (TTM)?
Ipsen S.A. EPS is 7.4 EUR over the trailing 12 months.
Which sector does the Ipsen S.A. company belong to?
The Ipsen S.A. sector is Healthcare.